Mike Tyson praises Trump for cannabis executive order, predicts it will allow 500,000 jobs to be counted

President Trump issued an executive order rescheduling marijuana from DEA Schedule I to Schedule III, a change that lowers federal restrictions, facilitates research into medical benefits and could ease commerce and counting of roughly 500,000 cannabis-related jobs. High-profile supporters including Mike Tyson praised the move and urged further steps such as clemency for nonviolent offenders and reforms to discriminatory banking practices that have constrained the industry. For investors, the order materially improves the regulatory outlook for cannabis companies by reducing legal risk and potentially increasing access to banking and capital, although implementation details and subsequent regulatory or legislative actions remain key uncertainties.

Analysis

Market structure: Rescheduling to Schedule III materially reduces regulatory friction for large licensed multi-state operators (MSOs), banks, and cannabis-adjacent suppliers (packagers, hydroponics). Winners: large-cap MSOs (TLRY, CGC, CRON), banking/fintech firms that open merchant services, and ag/ancillary suppliers (SMG); losers: illicit sellers, some small high-cost state-only operators, and vendors facing margin compression as supply scales. Expect faster capital access and M&A which will compress gross margins for low-quality producers but expand addressable market by 20–40% over 12–36 months if interstate commerce or federal guidance follows.

Risk assessment: Tail risks include rapid policy reversal, Congressional pushback, or delayed IRS/FDA/Treasury guidance (high-impact within 3–12 months). Immediate market moves (days) will be headline-driven and volatile; 1–6 month horizon depends on banking guidance and 280E tax enforcement; 1–3 year outcome hinges on full federal legalization and interstate logistics. Hidden dependencies: state licensing caps, 280E tax code persistence, and liability/health research (e.g., JAMA cardio study) that could trigger labeling/marketing limits.

Trade implications: Tactical overweight in large, cash-rich MSOs and ancillary suppliers via 2–3% positions (TLRY, CGC, SMG) with 6–12 month LEAPS call spreads (buy 12–18 month ITM calls, sell higher strike to fund). Pair trade: long TLRY (2%) / short a weaker small-cap MSO (1%) to capture consolidation. Rotate out of partial alcohol exposure (reduce BUD by 1–2%) into cannabis ETF MSOS on 10–30% pullbacks; add if Treasury issues formal banking guidance within 60 days.

Contrarian view: Market may be underpricing continued structural frictions — 280E, state rules, and slower bank uptake could delay revenue recognition 6–18 months, making near-term rallies overstretched. Historical parallel: Canadian legalization created an early speculative run followed by 18–36 month consolidation; expect similar volatility and selective winners. Unintended consequence: accelerated supply and commoditization could depress prices 10–30% in some states before premium branding benefits materialize.

Key Decisions for Investors

• Establish a 2–3% long position in Tilray Brands (TLRY) via a 12–18 month call spread (buy 2026 Jan 15–25% ITM calls, sell calls 30–40% above) within the next 30 days to capture rescheduling-driven rerating while limiting premium.
• Add a 1–2% tactical long in Canopy Growth (CGC) and a 1% long in Scotts Miracle-Gro (SMG) to play ancillary demand; size increases to 4–5% combined only after Treasury issues formal banking guidance or after MSOS ETF rises >20% on sustained volume.
• Implement a pair trade: long TLRY (2%) / short a weak small-cap US MSO (1%, choose the weakest balance sheet name in your coverage) to capture consolidation; rebalance if the spread narrows >15% or after 6 months.
• Reduce alcohol exposure by 1–2% (e.g., trim BUD) and redeploy proceeds into MSOS or TLRY on <10% pullbacks; exit if federal 280E tax guidance explicitly keeps treatment unchanged beyond 90 days.
• Monitor three catalysts over the next 60–90 days (Treasury/FinCEN banking guidance, IRS 280E guidance, and any FDA scheduling or labeling rules); if two appear favorable, increase cannabis exposure to 4–5% total portfolio weight within 30 days.